Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug dataset

JAAD International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles